Get started
Author

Connie Honeycutt

Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma
2006 · John D. Roberts, Mitchell R. Smith, et al. · Clinical Cancer Research · 39
A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
2013 · Beata Holkova, Jeffrey G. Supko, et al. · Clinical Cancer Research · 35
Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms
2014 · Beata Holkova, Maciej Kmieciak, et al. · Clinical Cancer Research · 26
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies
2012 · Prithviraj Bose, Edward B. Perkins, et al. · Cancer Chemotherapy and Pharmacology · 19
Supplementary Methods from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
2023 · Beata Holkova, Jeffrey G. Supko, et al.
PDF
Supplementary Table 2 from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
2023 · Beata Holkova, Jeffrey G. Supko, et al.
Supplementary Table 3 from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
2023 · Beata Holkova, Jeffrey G. Supko, et al.
Supplementary Table 1 from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
2023 · Beata Holkova, Jeffrey G. Supko, et al.
PDF
Supplementary Materials from Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms
2023 · Beata Holkova, Maciej Kmieciak, et al.
Data from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
2023 · Beata Holkova, Jeffrey G. Supko, et al.
Data from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
2023 · Beata Holkova, Jeffrey G. Supko, et al.
Data from Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms
2023 · Beata Holkova, Maciej Kmieciak, et al.
Data from Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms
2023 · Beata Holkova, Maciej Kmieciak, et al.
Supplementary Table 1 from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
2023 · Beata Holkova, Jeffrey G. Supko, et al.
Supplementary Table 2 from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
2023 · Beata Holkova, Jeffrey G. Supko, et al.
PDF
Supplementary Methods from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
2023 · Beata Holkova, Jeffrey G. Supko, et al.
Supplementary Table 3 from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
2023 · Beata Holkova, Jeffrey G. Supko, et al.
PDF
Supplementary Materials from Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms
2023 · Beata Holkova, Maciej Kmieciak, et al.
Works count: 18
Citation count: 119
H-index: 4
I10-index: 4
Year
Topic
Type